Myung Soo Park

Myung Soo Park

Auto-generated profile, based on publicly available information

Myung Soo Park

Division of Cardiology, Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
MPMyung Soo Park
Myung Soo Park
EKEung Ju Kim
Eung Ju Kim
Park MS, et al. J Korean Med Sci. 2023 Sep;38(39):e334. https://doi.org/10.3346/jkms.2023.38.e334

1 October 2021 in Clinical Therapeutics
Verified
Journal Article
Open access
MPMyung Soo Park
Myung Soo Park
JYJong-Chan Youn
Jong-Chan Youn
EKEung Ju Kim
Eung Ju Kim
KHKi Hoon Han
Ki Hoon Han
SLSang Hak Lee
Sang Hak Lee
KRKyu-Hyung Ryu
Kyu-Hyung Ryu
Residual cardiovascular risk reduction by fenofibrate in patients with high serum triglyceride (TG) levels despite previous statin monotherapy is not well characterized. The purpose of this study was to evaluate the efficacy and safety of a combination of choline fenofibrate and statin in patients with inadequately controlled TG levels despite previous statin monotherapy. This prospective, multicenter, randomized, double-blind study was conducted in Korea. A total of 133 patients with controlled LDL-C but elevated TG levels, already receiving statin monotherapy, were enrolled in the study, which was conducted from July 2018 to December 2019. Patients were randomly assigned to receive combination therapy with choline fenofibrate and statin or statin monotherapy in a 1:1 ratio. After 8 weeks of treatment, the lipid profiles and safety parameters of the patients in the 2 groups were compared. The study included 127 patients (64 in the combination group and 63 in the control group) older than 19 years. After 8 weeks of therapy, mean serum TG levels significantly decreased from 269.8 to 145.5 mg/dL (P < 0.0001) in the combination therapy group, whereas no significant changes occurred in the statin monotherapy group (from 271.1 to 280.5 mg/dL). Contrarily, the mean serum HDLC levels significantly increased from 45.0 to 50.4 mg/dL (P = 0.0004) in the combination therapy group, whereas there were no significant changes in the monotherapy group (from 44.3 to 44.7 mg/dL). There were no additional serious adverse events in the combination therapy group compared with the statin monotherapy group. The combination therapy using choline fenofibrate and statin was found to be effective in serum TG control and likely tolerable in patients with high TG levels despite statin monotherapy. A larger study, conducted for a longer duration, is needed to evaluate the effectiveness of this combination in reducing cardiovascular risk. ClinicalTrials.gov identifier: NCT03874260.

8 December 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MPMyung Soo Park
Myung Soo Park
SLSunki Lee
Sunki Lee
TATaehoon Ahn
Taehoon Ahn
DKDoyoung Kim
Doyoung Kim
MJMi-Hyang Jung
Mi-Hyang Jung
EKEung Ju Kim
Eung Ju Kim
Cardiac rehabilitation services are mostly underutilized despite the documentation of substantial morbidity and mortality benefits of cardiac rehabilitation post-acute myocardial infarction. To assess the implementation rate and barriers to cardiac rehabilitation in hospitals dealing with acute myocardial infarction in South Korea, between May and July 2016, questionnaires were emailed to cardiology directors of 93 hospitals in South Korea; all hospitals were certified institutes for coronary interventions. The questionnaires included 16 questions on the hospital type, cardiology practice, and implementation of cardiac rehabilitation. The obtained data were categorized into two groups based on the type of the hospital (secondary or tertiary) and statistically analysed. Of the 72 hospitals that responded (response rate of 77%), 39 (54%) were tertiary medical centers and 33 (46%) were secondary medical centers. All hospitals treated acute myocardial infarction patients and performed emergency percutaneous coronary intervention; 79% (57/72) of the hospitals performed coronary artery bypass grafting. However, the rate of implementation of cardiac rehabilitation was low overall (28%, 20/72 hospitals) and even lower in secondary medical centers (12%, 4/33 hospitals) than in tertiary centers (41%, 16/39 hospitals, p = 0.002). The major barriers to cardiac rehabilitation included the lack of staff (59%) and lack of space (33%). In contrast to the wide availability of acute-phase invasive treatment for AMI, the overall implementation of cardiac rehabilitation is extremely poor in South Korea. Considering the established benefits of cardiac rehabilitation in patients with acute myocardial infarction, more administrative support, such as increasing the fee for cardiac rehabilitation services by an appropriate level of health insurance coverage should be warranted.

1 January 2024 in International Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
Jah Yeon ChoiJah Yeon Choi
Jah Yeon Choi
MKMi-Na Kim
Mi-Na Kim
SHSeongwoo Han
Seongwoo Han
SLSunki Lee
Sunki Lee
MPMyung Soo Park
Myung Soo Park
OIon behalf of SMILE HF Investigators
on behalf of SMILE HF Investigators
Choi JY, et al. Int J Heart Fail. 2024 Jul;6(3):129-136. https://doi.org/10.36628/ijhf.2024.0014

8 January 2026 in ESC Heart Failure
Verified
Journal Article
Open access
SSSangho Sohn
Sangho Sohn
Jah Yeon ChoiJah Yeon Choi
Jah Yeon Choi
MKMi-Na Kim
Mi-Na Kim
SHSeongwoo Han
Seongwoo Han
MPMyung Soo Park
Myung Soo Park
EKEung Ju Kim
Eung Ju Kim
Introduction: Residual congestion at discharge is an important risk factor for early readmission and mortality in acute heart failure (AHF); however, it is often underestimated. This study aimed to evaluate the clinical value of oedema index (EI) and phase angle (PA) from bioelectrical impedance analysis (BIA) in assessing residual congestion and predicting short-term outcomes in patients with AHF. Methods: A multi-centre registry database from the steady movement with innovating leadership for heart failure (HF) between 2019 and 2023 was analysed. EI and PA were measured using direct segmental multi-frequency BIA device. The worsening heart failure events (WHF) were defined as a composite of HF readmission and all-cause mortality at 90- and 180-days. Receiver operating characteristic analysis determined the EI and PA cut-off values. Logistic regression and Cox proportional hazard analyses were used to assess the associations between BIA parameters and clinical outcomes. Results: A total of 600 patients were included, of whom 360 (60%) were male, with a median age of 72.1 years. Within 180 days, 63 patients (11%) experienced WHFs. EI (odds ratio [OR] 1.83; 95% confidence interval [CI] 1.43–2.35 at 90 days, OR 1.76; CI 1.44–2.14 at 180 days, all P < .01) and PA (OR 0.93; CI 0.90–0.96 at 90 days, OR 0.94; CI 0.91–0.96 at 180 days, all P < .01) showed correlation in univariate analysis. EI ≥ 0.4 and PA < 4.5° were identified as prognostic thresholds for unfavourable outcomes, with predictive values of 75% (P < .01, sensitivity 83%, and specificity 56%), and 71% (P < .01, sensitivity 81%, and specificity 54%), respectively. Increased EI (adjusted hazard ratio [aHR] 1.71; CI 1.26–2.31 at 90 days, aHR 1.64; CI 1.30–2.07 at 180 days, all P < .01) and decreased PA (aHR 0.91; CI 0.86–0.96 at 90 days, aHR 0.92; CI 0.89–0.97 at 180 days, all P < .01) were independently associated with WHFs. Based on the estimated cut-offs, when EI and PA were considered together to classify the high-risk BIA group (EI ≥ 0.4 and PA < 4.5°), the risk was apparently increased (aHR 6.79; CI 1.71–26.93 at 90 days, aHR 3.43; CI 1.41–8.32 at 180 days, all P < .05) compared with normal BIA (EI < 0.4 and PA ≥ 4.5°) group. Conclusion: The EI and PA measured at discharge independently predicted short-term WHFs in patients with AHF. The suggested thresholds for identifying patients at high-risk of residual congestion were EI ≥ 0.4 and PA < 4.5°. As a non-invasive and accessible modality, BIA holds promise as a complementary tool to established biomarkers for evaluating congestion at discharge.

14 October 2022 in International Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
DCDae Young Cheon
Dae Young Cheon
SLSunki Lee
Sunki Lee
MPMyung Soo Park
Myung Soo Park
DKDo Young Kim
Do Young Kim
MJMi-Hyang Jung
Mi-Hyang Jung
KRKyu-Hyung Ryu
Kyu-Hyung Ryu
Cheon DY, et al. Int J Heart Fail. 2022 Oct;4:e19. https://doi.org/10.36628/ijhf.2022.0019